Two-Pronged attack on deadly breast cancer shows promise
Disease control
Recruiting now
This study is testing whether a combination of two drugs, trastuzumab deruxtecan and durvalumab, can effectively shrink tumors before surgery in people with stage III inflammatory breast cancer that expresses the HER2 protein. The goal is to see if this pre-surgery treatment can …
Phase: PHASE2 • Sponsor: Filipa Lynce, MD • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC